Hydroxyurea in Young Children With Sickle Cell Anemia

Completed · Not applicable

Conditions studied: Sickle Cell Anemia

In brief

The purpose of this study is to asses prospectively the safety and efficacy of hydroxyurea therapy in children with Sickle cell Anemia between ages 18 months and 5 years, with special emphasis on the ability of hydroxyurea to prevent or reverse chronic organ damage.

Key facts

Study ID

NCT00519701

Run by

Duke University

People needed

14

Starts

2002-04-01

Expected to finish

2007-02-01

Last updated by the study team

2007-08-23

Who can join

Age: 2 and older, up to 5. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Sickle Cell Anemia (Hb SS or Hb S beta zero-thalassemia)

Where it is running

• Duke University Medican Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.